These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32434399)

  • 1. Pre-eclampsia screening in the first trimester - preemptive action to prevent the peril.
    Vikraman SK; Elayedatt RA
    J Matern Fetal Neonatal Med; 2022 May; 35(9):1808-1816. PubMed ID: 32434399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population.
    Chaemsaithong P; Pooh RK; Zheng M; Ma R; Chaiyasit N; Tokunaka M; Shaw SW; Seshadri S; Choolani M; Wataganara T; Yeo GSH; Wright A; Leung WC; Sekizawa A; Hu Y; Naruse K; Saito S; Sahota D; Leung TY; Poon LC
    Am J Obstet Gynecol; 2019 Dec; 221(6):650.e1-650.e16. PubMed ID: 31589866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
    Tan MY; Syngelaki A; Poon LC; Rolnik DL; O'Gorman N; Delgado JL; Akolekar R; Konstantinidou L; Tsavdaridou M; Galeva S; Ajdacka U; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Aug; 52(2):186-195. PubMed ID: 29896812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment.
    Wright D; Tan MY; O'Gorman N; Syngelaki A; Nicolaides KH
    BJOG; 2022 Jul; 129(8):1308-1317. PubMed ID: 35015330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of first-trimester combined screening for early-onset and preterm pre-eclampsia at 8-10 compared with 11-13 weeks' gestation.
    Mendoza M; Garcia-Manau P; Arévalo S; Avilés M; Serrano B; Sánchez-Durán MÁ; Garcia-Ruiz I; Bonacina E; Carreras E
    Ultrasound Obstet Gynecol; 2021 Jan; 57(1):84-90. PubMed ID: 32388877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE.
    Tan MY; Wright D; Syngelaki A; Akolekar R; Cicero S; Janga D; Singh M; Greco E; Wright A; Maclagan K; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):743-750. PubMed ID: 29536574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASPRE trial: performance of screening for preterm pre-eclampsia.
    Rolnik DL; Wright D; Poon LCY; Syngelaki A; O'Gorman N; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Papaioannou G; Tenenbaum-Gavish K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Oct; 50(4):492-495. PubMed ID: 28741785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First trimester preeclampsia screening and prediction.
    Chaemsaithong P; Sahota DS; Poon LC
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1071-S1097.e2. PubMed ID: 32682859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
    O'Gorman N; Wright D; Syngelaki A; Akolekar R; Wright A; Poon LC; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jan; 214(1):103.e1-103.e12. PubMed ID: 26297382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
    Francisco C; Wright D; Benkő Z; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Nov; 50(5):589-595. PubMed ID: 28556556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
    Benkő Z; Wright A; Rehal A; Cimpoca B; Syngelaki A; Delgado JL; Tsokaki T; De Alvarado M; Vojtassakova D; Malligiannis Ntalianis K; Chaveeva P; Del Campo A; De Ganzo T; Resta C; Atanasova V; Accurti V; Villalain C; Aguilera J; Dojcinovska D; O'Gorman N; Plasencia W; Zingler E; Dutemeyer V; Alvar B; Casanova MC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Feb; 57(2):257-265. PubMed ID: 33142361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-stage screening for preterm preeclampsia at 11-13 weeks' gestation.
    Wright A; Wright D; Syngelaki A; Georgantis A; Nicolaides KH
    Am J Obstet Gynecol; 2019 Feb; 220(2):197.e1-197.e11. PubMed ID: 30414394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
    Tan MY; Poon LC; Rolnik DL; Syngelaki A; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Jul; 52(1):52-59. PubMed ID: 29704277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis.
    Shen L; Martinez-Portilla RJ; Rolnik DL; Poon LC
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):546-552. PubMed ID: 33998099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
    Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
    Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contingent screening for preterm pre-eclampsia.
    Wright D; Gallo DM; Gil Pugliese S; Casanova C; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 May; 47(5):554-9. PubMed ID: 26643929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China.
    Hu J; Gao J; Liu J; Meng H; Hao N; Song Y; Ma L; Luo W; Sun J; Gao W; Meng W; Sun Y
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):529-539. PubMed ID: 33817865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 19-23 weeks' gestation.
    Sapantzoglou I; Wright A; Arozena MG; Campos RV; Charakida M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Jan; 57(1):75-83. PubMed ID: 33142353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.